Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q3 2024 Xvivo Perfusion AB Earnings Call Transcript

Oct 24, 2024 / 12:00PM GMT
Release Date Price: kr477.5 (-1.35%)
Christoffer Rosenblad
Xvivo Perfusion AB - CEO

And welcome to Xvivo's earning call for the third quarter of 2024.

On the first light today's presentation that are sitting in the same room, Christopher Rosengard co and besides me, Kristoffer Nordstrom CFO of X Perfusion.

And with that, we turn to slide 2 the Q3 financials at a glance and, and I'm proud and happy to report that Q3 shows improving our top line as well as EBITA compared to the same quarter last year, even though we have continued and we will continue to invest in the organization for for future growth. Sales came in at 191 million, which is the 41% organic growth and their data shows an improvement to 21%.

The growth for is main Forex is mainly coming from higher PS activity during the quarter. Another growth that we see in this quarter is the US R trial where we are seeing very high interest to join the trial as well as well as very high activity in the trial during the summer months.

And Kristoffer Nordstrom, our Chief Financial Officer will get into the details on sale, gross margin avatar and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot